Stay updated on Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4, indicating a newer page version. This appears to be a minor technical update to the page rather than a change to study details.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page revision was updated from v3.6.0 to v3.6.3, indicating a newer published version of the study record. This is a maintenance update that does not modify the study data or other substantive content on the page.SummaryDifference0.1%

- Check48 days agoChange DetectedThe study record now indicates that recruitment is closed and no longer looking for participants. Additionally, new help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), the Intervention/Treatment label was reformatted, and the revision version updated to v3.6.0.SummaryDifference0.4%

- Check55 days agoChange DetectedThe page revision tag was updated from v3.5.4 to v3.5.5, reflecting an editorial update to the page metadata.SummaryDifference0.1%

- Check77 days agoChange DetectedNew Revision: v3.5.4 appears on the page, replacing the old v3.5.3 tag. This is a minor metadata update to the page, not altering the study content or results.SummaryDifference0.1%

- Check98 days agoChange DetectedUpdated the site’s displayed release/revision version from **v3.5.2** to **v3.5.3** at the bottom of the page.SummaryDifference0.1%

Stay in the know with updates to Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial page.